The basic structure and biological function of cholera toxin (CT) and heatlabile toxin of enterotoxigenic Escherichia coli (LT), which induces diarrhea in humans, are similar. Both CT and LT act as adjuvants for the enhancement of mucosal and serum antibody responses to the mucosally co-administered protein antigen. CT acts as an adjuvant by inducing IL-4-dependent Th2 cytokine responses, which provide help for antigen-specific secretory IgA (S-IgA) as well as serum IgGl, IgA and IgE antibody responses. On the other hand, LT induces Thl-and partly IL-4-independent Th2-type cells with subsequent serum IgGl, IgG2a and mucosal S-IgA responses. Nontoxic mutant CT (mCT) and the chimeric molecule that combine the A subunit of mCT with the B subunit of LT (mCTA/LTB),like nCT, act as mucosal adjuvants and induce mucosal IgA and systemic IgG and IgA antibody responses. These studies indicate that ADPribosyltransferase activity can be separated from the adjuvant properties of CT and LT. Further, those nontoxic enterotoxin derivatives should be considered as candidate mucosal adjuvants for vaccinating humans.
Introduction
The mucosal surface areas where most pathogens enter the host are protectedby antibodies of the secretory IgA (SIgA). This isotype constitutes more than 80 % of all antibodies produced in mucosa-associated tissues, and SIgA antibodies are induced, transported, and regulated by a unique mechanism of mucosal intranet consisting of Thl/ Th2 cells, IgA committed B cells, dendritic cells and epithelial cells that is completely different from those involved in systemic antibody responses (1) . The mucosal immune system is an integrated network of tissues, cells and effector molecules, which protects the host from environmental pathogens and antigens. Mucosal lymphocytes exhibituniquehomingreceptors, integrins and chemokine receptors, which recognize ligands expressed on mucosal endothelial cells, allowing their specific migration to and retention in mucosal tissues for the induction and regulation of antigen-specific S-IgA in external secretions (1) . Thus, the mucosal immune system is separatefrom the peripheral lymphoid tissues providing immuneprotectionfor internal organs and tissues.Therefore, the induction of peripheral immune responses by parental immunization does not result in significant mucosal immunity (1) . In contrast, mucosal immunization results in the generation of protective immunity in external secretions and in the peripheral compartment as well. For the control of infectious diseases, mucosal vaccination becomes an attractive approach since it possesses a capability of maximally generating antigen-specific immune responses at both external and internal compartments of the host. To accomplish this goal, different forms of mucosal adjuvant, vector, and delivery system are being investigated for their ability to induce well-defined immune responses to protect individuals from mucosal pathogens (1) . In this regard, cholera toxin (CT) is an effective mucosal adjuvant that can support the induction of antigen-specific mucosal and systemic immune responses against coadministered protein antigen (2-7). In this article, we will summarize our recent progress in the characterization of molecular and cellular mechanisms formucosaladjuvantactivity of CT in comparison toitsrelated heatlabile toxin(LT) ofenterotoxigenic Escherichia coli(ETEC). Further, wewillbriefly summarize thedevelopment of mutant derivatives of CT and LT as novel nontoxic mucosal adjuvants.
The mucosal immune system
The mucosal immune system is anatomically and functionally divided into sites where foreign antigens are encountered and selectively taken up for initiation of immune responses and the more diffuse collections of B and T cells, plasma cells, and antigen-presenting cells, which comprise the effector cells for induction and regulation of mucosal immunity. Collectively, these tissues associated with this activity are known as inductive sites. In case of the intestinal tract, Peyer's patches are the most well characterized tissue which represent gut-associated lymphoreticular tissue (GALT), a major inductive site for orally administered antigens (1) . On the other hand, the major inductive sites for nasal/inhaled antigens appear to be the palatine tonsils and adenoids, which togetherform a physicalbarrier of lymphoid tissues termed the Waldeyer's ring, now more frequently referred to as a nasopharyngealassociated lymphoreticular tissue (NALT) (1).
Peyer's patches, a well characterized GALT, have been shown to be the major inductive sites for the initiationof SIgA antibody responses in the gastrointestinal tract. The 
CT and LT as mucosal adjuvants
The basic structure and biological function of CT and LT, which induces diarrhea in humans, are similar; however, the infection caused by the former molecule is associated with a more severe, cramping diarrhea (15) (16) (17) . The nucleotide sequences of the two toxins are approximately 80% homologous (18, 19) . Both CT and LT consist of an enzymatically active A subunit separated from the plane of a ring formed by five smaller, identical B subunits (20, 21) . The A subunit is composed of a globular structure linked to the B subunit by a trypsin-sensitive loop and a long a helix, the C-terminus, which enters into the central cavity of the B subunit, thus anchoring the A subunit to the B pentamer (21) . The A subunit contains an ADP-ribosyltransferase active pocket that binds nicotinamide adenine dinucleotide (NAD) and catalyzes ADP ribosylation of Gsa (22 shows a different fine specificity between CT and LT. The B pentamer of CT (CT-B) selectively binds GM1, whereas LT-B is ligandfor GM1, GM2 and asialoGM1 cell surface receptors (24) (25) (26) . The different receptorbinding activities of the CT and LTmay promote differentadjuvantproperties that are exhibited by two molecules, as will be discussed below.
CT and LT are potent immunogens and induce antigenspecific S-IgA and serum IgG and IgA antibody responses (27) (28) (29) . Furthermore, both toxins can act as adjuvants for the enhancement of mucosal and serum antibody responses to mucosally co-administered protein antigen (2-7, 30, 31). CT acts as adjuvant by inducing CD4+ Th2 cells secreting EL-4, IL-5, IL-6 and IL-10, which provide help for antigenspecificS-IgA as well as serum IgGl, IgA and IgE antibody responses (4, 7). CT has also been shown to selectively inhibit proliferation of CD4+ Thl, but not of Th2, cell lines stimulated by anti-CD3 monoclonal antibody or by PMA and ionomycin (32) . Further, CT facilitated B cell switching to IgA and increased the effects of IL-4 and IL-5 on IgG and IgA synthesis in LPS-triggered splenic B cell cultures (33, 34) . In addition to these unique immunological characteristic of CT shown by the murine studies, it was also shown that nasal immunization of rhesus macaques with p55gag of simian immunodeficiency virus (SIV) plus CT elicit SIV-specific S-IgA antibody and CTL responses in both mucosal and systemic compartments (35) . These additional immunological features of CT further provide supportive evidence for potential usage of the enterotoxin as mucosal adjuvant if one could genetically separate toxicity and immune enhancing activity.
Like the related CT, LT has been widely used for studies of mucosal immunity (2, 30, (36) (37) (38) . Mucosal immunization of mice with Ag and LT induced mixed CD4+ Thl-and Th2-type cells with subsequent mucosal S-IgA antibody responses (30) . Further, our previous study has shown that LT promotes mucosal IgA antibody responses by an IL-4-independent mechanism (39). In contrast, it was shown that CT provides its adjuvant activity via the IL-4 dependent manner (6, 7, 39) . Since LT differ from CT in terms of the type of immune responses (CT for Th2 while LT for both Thl andTh2), we can select most suitablemucosal adjuvant for each vaccine based on the nature of infectious agents. In summary, several lines of evidence indicate that CT and LT as mucosal adjuvant are capable of inducing both humoral and cell-mediated immunity in systemic and mucosal compartments.
Mechanisms for adjuvant effect of enterotoxins
CD28 on T cells provides a potent co-stimulatory signal following interactions with B7-1 (CD80) and B7-2 (CD86) expressed on antigen-presenting cells (40) . With regard to the involvement of CD28/B7 signaling in the adjuvanticity of CT, it has been reported that both native CT and a fusion protein with the intact A1 subunit enhanced B7-1 and B7-2 expression on B cells (41) . In contrast, other studies have shown that CT enhances B7-2, but not B7-1, expression by macrophages and administration of anti-B7-2 monoclonal antibodies inhibited keyhole limpet hemocyanin (KLH)-specific serum IgG and mucosal IgA antibody responses in mice given KLH plus CT orally (42) . Our studies have shown that both CT and LTenhances B7-2 expressionon B cells and macrophages in Peyer's patches (39) . Further, additionof LT-or CT-treatedantigen-presenting cells to anti-CD3 triggered CD4+ T cells resulted in the induction of T cell proliferative responses. Moreover, these responses were inhibited by monoclonal antibodies to B7-2 (39), implying that the CD28/B7-2 signaling pathway is of major importance for the adjuvant activity of both enterotoxins (Fig. 2) . Interestingly, most recent studies have shown that oral immunization of CTLA4-H1 transgenic mice with CT as adjuvant failed to induce antigen-specific antibody responses in both mucosal and systemic compartment. On the other hand, CD287 mice developed near normal gut mucosal IgA responses but poor serum antibody responses (43) . These results suggest that alternative costimulatory pathways in addition to CD28/B7-2 are involved for the induction of adjuvant activity of CT.
Both CT and LT can directly affect T cells; however, LT differs from CT in terms of the regulation of Thl and Th2 cell responses. CT inhibits proliferative responses and cytokine synthesis of Thl clones, but had no effect on Th2 (Fig. 2) .
Nontoxic mutant enterotoxins as a new generation mucosal adjuvant
Despite the potent mucosal adjuvant activity of native (n) CT and nLT, both enterotoxins cause severe diarrhea and are thus unsuitable for use in humans (28) . Therefore, a number of nontoxic mutant derivatives of CT or LT have been constructed (36, (45) (46) (47) (48) (49) (50) . We have also generated mutant (m) CT by substituting a single amino acid in the ADPribosyltransferase active center of the A subunit and have created two mutants of CT (S61F and El 12K) (52) (Fig. 3) . These two gene manipulated forms of mCT did not induce ADP-ribosylation, cAMP formation, or fluid accumulation in ligated ileal loops and thus are nontoxic (51) . Importantly, these mCTs still supported antigen-specific immune responses when co-administered parenterally with protein antigen (51) . Further, we have demonstrated that mCT acts 
